Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18906021 | 0.86 | KMT2A (0.61) | KMT2AALDH1A1TP53HPGDGAA | |
| SCHEMBL8338185 | 0.85 | KMT2A (0.56) | KMT2AALDH1A1TP53HPGDGAA | |
| SCHEMBL1106975 | 0.84 | KMT2A (0.62) | KMT2AALDH1A1TP53HPGDGAA | |
| SCHEMBL27281106 | 0.83 | ALDH1A1 (0.62) | KMT2AALDH1A1TP53HPGDGAA | |
| SCHEMBL18546466 | 0.83 | ALDH1A1 (0.62) | KMT2AALDH1A1TP53HPGDGAA | |
| SCHEMBL14664119 | 0.82 | KMT2A (0.54) | KMT2AALDH1A1TP53HPGDGAA | |
| SCHEMBL9200428 | 0.81 | KMT2A (0.59) | KMT2AALDH1A1TP53HPGDGAA | |
| SCHEMBL10868007 | 0.80 | ALDH1A1 (0.55) | KMT2AALDH1A1TP53HPGDGAA | |
| SCHEMBL10868004 | 0.80 | ALDH1A1 (0.55) | KMT2AALDH1A1TP53HPGDGAA | |
| SCHEMBL21041221 | 0.78 | KMT2A (0.68) | KMT2AALDH1A1TP53GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | KMT2A 3866/4885ALDH1A1 3778/4885TP53 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.